Enzastaurin: A lesson in drug development

Molecular Biology of the Cell

Alberts, B., Johnson, A., Lewis, J. H., Morgan, D. O., RAFF, M. C., Roberts, K. J., & Walter, P. (2017) · W.W. Norton eBooks · doi:10.1201/9781315735368 · Cited by 7,937 · see citing works

Raise standards for preclinical cancer research

Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979 · see citing works

A quantitative analysis of kinase inhibitor selectivity

Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466 · see citing works

Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinase

Tamaoki, T., Nomoto, H., TAKAHASHI, I., Kato, Y., Morimoto, M., & Tomita, F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90008-2 · Cited by 2,452 · see citing works

Protein Kinase C: Structure, Function, and Regulation

Newton, A. C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.48.28495 · Cited by 1,662 · see citing works

Multiple, Distinct Forms of Bovine and Human Protein Kinase C Suggest Diversity in Cellular Signaling Pathways

Coussens, L. M., Parker, P. J., Rhee, L. M., Yang‐Feng, T. L., Chen, E., Waterfield, M. D., Francke, U., & Ullrich, A. (1986) · Science · doi:10.1126/science.3755548 · Cited by 1,042 · see citing works

Protein kinase C and other diacylglycerol effectors in cancer

Griner, E. M., & Kazanietz, M. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2110 · Cited by 978 · see citing works

Localization of Protein Kinases by Anchoring Proteins: a Theme in Signal Transduction

Mochly‐Rosen, D. (1995) · Science · doi:10.1126/science.7716516 · Cited by 905 · see citing works

Protein kinase C as a possible receptor protein of tumor‐promoting phorbol esters

Kikkawa, U., Takai, Y., Tanaka, Y., Miyake, R., & Nishizuka, Y. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44245-1 · Cited by 881 · see citing works

The Complete Primary Structure of Protein Kinase C—the Major Phorbol Ester Receptor

Parker, P. J., Coussens, L. M., Totty, N., Rhee, L. M., Young, S. R., Chen, E., Stabel, S., Waterfield, M. D., & Ullrich, A. (1986) · Science · doi:10.1126/science.3755547 · Cited by 854 · see citing works

Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins.

Dorit Ron, A., Chen, C., Caldwell, J., Jamieson, L., Orr, E., & Mochly‐Rosen, D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.3.839 · Cited by 723 · see citing works

The structure, expression, and properties of additional members of the protein kinase C family.

Ono, Y., Fujii, T., Ogita, K., Kikkawa, U., Igarashi, K., & Nishizuka, Y. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68732-0 · Cited by 692 · see citing works

Isolation and structure of bryostatin 1

Pettit, G. R., Herald, C. L., Doubek, D. L., Herald, D. L., Arnold, E., & Clardy, J. (1982) · Journal of the American Chemical Society · doi:10.1021/ja00388a092 · Cited by 653 · see citing works

Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum.

Takai, Y., Kishimoto, A., Inoue, M., & Nishizuka, Y. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41009-x · Cited by 595 · see citing works

VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells

Takahashi, T., Ueno, H., & Shibuya, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202527 · Cited by 572 · see citing works

Protein kinase C, an elusive therapeutic target?

Mochly‐Rosen, D., Das, K., & Grimes, K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 565 · see citing works

Opposing cardioprotective actions and parallel hypertrophic effects of δPKC and ɛPKC

Chen, L., Hahn, H. S., Wu, G., Chen, C., Liron, T., Schechtman, D., Cavallaro, G., Banci, L., Guo, Y., Bolli, R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191369098 · Cited by 537 · see citing works

Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C

Wilkinson, S. E., Parker, P. J., & Nixon, J. (1993) · Biochemical Journal · doi:10.1042/bj2940335 · Cited by 522 · see citing works

Identification of intracellular receptor proteins for activated protein kinase C.

Mochly‐Rosen, D., Khaner, H., & Lopez, J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.9.3997 · Cited by 500 · see citing works

Overproduction of protein kinase C causesdisordered growth control in rat fibroblasts

Housey, G. M., Johnson, M. D., Hsiao, W. L. W., O’Brian, C. A., Murphy, J. P., Kirschmeier, P. T., & Weinstein, I. B. (1988) · Cell · doi:10.1016/s0092-8674(88)80027-8 · Cited by 478 · see citing works

Potent selective inhibitors of protein kinase C

Davis, P. D., Hill, C. H., Keech, E., Lawton, G., Nixon, J., Sedgwick, A. D., Wadsworth, J., Westmacott, D., & Wilkinson, S. E. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)81494-2 · Cited by 478 · see citing works

In vitro studies on the mode of action of the phorbol esters, potent tumor promoters: Part 1

Blumberg, P. M., & Boutwell, R. K. (1980) · Critical Reviews in Toxicology · doi:10.3109/10408448009037493 · Cited by 475 · see citing works

The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

Graff, J. R., McNulty, A. M., Hanna, K. R., Konicek, B. W., Lynch, R. L., Bailey, S. N., Banks, C., Capen, A. R., Goode, R. L., Lewis, J. E., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0071 · Cited by 441 · see citing works

Tissue and cellular distribution of the extended family of protein kinase C isoenzymes

Wetsel, W. C., Khan, W. A., Merchenthaler, I. J., Rivera, H., Halpern, A. E., Phung, H., Negro-Vilar, A. F., & Hannun, Y. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.117.1.121 · Cited by 440 · see citing works

Decrease in cytosolic calcium/phospholipid-dependent protein kinase activity following phorbol ester treatment of EL4 thymoma cells.

Kraft, A. S., Anderson, W. B., Cooper, H. L., & Sando, J. J. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33427-6 · Cited by 412 · see citing works

Targeting the protein kinase C family: are we there yet?

MacKay, H. J., & Twelves, C. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2168 · Cited by 373 · see citing works

Expression and Properties of Two Types of Protein Kinase C: Alternative Splicing from a Single Gene

Ono, Y., Kikkawa, U., Ogita, K., Fujii, T., Kurokawa, T., Asaoka, Y., Sekiguchi, K., Ase, K., Igarashi, K., & Nishizuka, Y. (1987) · Science · doi:10.1126/science.3576226 · Cited by 311 · see citing works

Role of Diacylglycerol-Regulated Protein Kinase C Isotypes in Growth Factor Activation of the Raf-1 Protein Kinase

Cai, H., Smola, U., Wixler, V., Eisenmann-Tappe, I., Díaz-Meco, M. T., Moscat, J., Rapp, U. R., & Cooper, G. M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.2.732 · Cited by 291 · see citing works

Clonogenic assay with established human tumour xenografts

Fiebig, H., Maier, A., & Burger, A. M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.009 · Cited by 290 · see citing works

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Robertson, M. J., Kahl, B. S., Vose, J. M., de Vos, S., Laughlin, M., Flynn, P. J., Rowland, K. M., Cruz, J. C., Goldberg, S. L., Musib, L. C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3146 · Cited by 232 · see citing works

Mechanism of action of the phorbol ester tumor promoters: Specific receptors for lipophilic ligands

Blumberg, P. M., Jaken, S., König, B., Sharkey, N. A., Leach, K. L., Jeng, A. Y., & Yeh, E. (1984) · Biochemical Pharmacology · doi:10.1016/0006-2952(84)90448-9 · Cited by 205 · see citing works

Protein kinase C isotypes in human erythroleukemia (K562) cell proliferation and differentiation. Evidence that beta II protein kinase C is required for proliferation

Murray, N. R., Baumgardner, G. P., Burns, D. J., & Fields, A. P. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82331-6 · Cited by 202 · see citing works

An autoregulatory region in protein kinase C: the pseudoanchoring site.

Ron, D., & Mochly‐Rosen, D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.2.492 · Cited by 200 · see citing works

UCN-01, a selective inhibitor of protein kinase C from Streptomyces.

TAKAHASHI, I., KOBAYASHI, E., Asano, K., Yoshida, M., & Nakano, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1782 · Cited by 186 · see citing works

Binding Specificity for RACK1 Resides in the V5 Region of βII Protein Kinase C

Stebbins, E. G., & Mochly‐Rosen, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101044200 · Cited by 183 · see citing works

Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis.

Yoshiji, H., Kuriyama, S., Ways, D. K., Yoshii, J., Miyamoto, Y., Kawata, M., Ikenaka, Y., Tsujinoue, H., Nakatani, T., Shibuya, M., et al. (1999) · PubMed · Cited by 183 · see citing works

Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.

Gökmen‐Polar, Y., Murray, N. R., Velasco, M. A. D., Gatalica, Z., & Fields, A. P. (2001) · PubMed · Cited by 181 · see citing works

Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer

Carducci, M. A., Musib, L. C., Kies, M. S., Пили, Р., Truong, M. T., Brahmer, J. R., Cole, P., Sullivan, R., Riddle, J. R., Schmidt, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3447 · Cited by 176 · see citing works

Bryostatins: Potent, new mitogens that mimic phorbol ester tumor promoters

Smith, J. B., Smith, L., & Pettit, G. R. (1985) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(85)91898-4 · Cited by 140 · see citing works

Protein Kinase C θ Is Highly Expressed in Gastrointestinal Stromal Tumors But Not in Other Mesenchymal Neoplasias

Blay, P., Astudillo, A., Buesa, J., Campo, E., Abad, M., García-García, J., Miquel, R., Marco, V., Sierra, M., Losa, R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0630 · Cited by 139 · see citing works

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Crump, M., Leppä, S., Fayad, L., Lee, J. J., Rocco, A. D., Ogura, M., Hagberg, H., Schnell, F. M., Rifkin, R. M., Mackensen, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7171 · Cited by 125 · see citing works

Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells

Stone, R. M., Sariban, E., Pettit, G., & Kufe, D. W. (1988) · Blood · doi:10.1182/blood.v72.1.208.208 · Cited by 122 · see citing works

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)

Podar, K., Raab, M. S., Zhang, J., McMillin, D. W., Breitkreutz, I., Tai, Y., Lin, B. K., Munshi, N. C., Hideshima, T., Chauhan, D., et al. (2006) · Blood · doi:10.1182/blood-2006-08-042747 · Cited by 119 · see citing works

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

Keyes, K. A., Mann, L. L., Sherman, M., Galbreath, E. J., Schirtzinger, L., Ballard, D. W., Chen, Y.-F., Iversen, P. W., & Teicher, B. A. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0713-x · Cited by 116 · see citing works

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

Kreisl, T. N., Kotliarova, S. E., Butman, J. A., Albert, P. S., Kim, L., Musib, L. C., Thornton, D., & Fine, H. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop042 · Cited by 109 · see citing works

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemia

Moreau, A.-S., Jia, X., Ngo, H. T., Leleu, X. P., O’Sullivan, G., Alsayed, Y. M., Leontovich, A. A., Podar, K., Kutok, J. L., Daley, J. F., et al. (2007) · Blood · doi:10.1182/blood-2006-10-054577 · Cited by 98 · see citing works

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

Morschhauser, F., Seymour, J. F., Kluin‐Nelemans, H. C., Grigg, A., Wolf, M., Pfreundschuh, M. G., Tilly, H., Raemaekers, J. M. M., Veer, M. B. V., Milpied, N. J., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm463 · Cited by 97 · see citing works

Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas

Fine, H. A., Kim, L., Royce, C., Draper, D., Haggarty, I., Ellinzano, H., Albert, P. S., Kinney, P., Musib, L. C., & Thornton, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.1504 · Cited by 96 · see citing works

Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβ

Faul, M. M., Gillig, J. R., Jirousek, M. R., Ballas, L. M., Schotten, T., Kahl, A., & Mohr, M. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00286-5 · Cited by 93 · see citing works

Antiangiogenic effects of a protein kinase Cβ-selective small molecule

Teicher, B. A., Álvarez, E., Menon, K., Esterman, M. A., Considine, E. L., Shih, C., & Faul, M. M. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-001-0386-2 · Cited by 91 · see citing works

The Selective Protein Kinase C β Inhibitor Enzastaurin Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines through the AKT Pathway

Querfeld, C., Rizvi, M. A., Kuzel, T. M., Guitart, J., RADEMAKER, A. W., Sabharwal, S. S., Krett, N. L., & Rosen, S. T. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700322 · Cited by 89 · see citing works

Alternative Splicing Increases the Diversity of the Human Protein Kinase C Family

Coussens, L. M., Rhee, L. M., Parker, P. J., & Ullrich, A. (1987) · DNA · doi:10.1089/dna.1987.6.389 · Cited by 82 · see citing works

Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines

Rizvi, M. A., Ghias, K. K., Davies, K. M., Ma, C., Weinberg, F. D., Munshi, H. G., Krett, N. L., & Rosen, S. T. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0465 · Cited by 81 · see citing works

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

Butowski, N. A., Chang, S. M., Lamborn, K. R., Polley, M.-Y., Pieper, R. O., Costello, J., VandenBerg, S. R., Parvataneni, R., Nicole, A., Sneed, P. K., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor130 · Cited by 77 · see citing works

Varied differentiation responses of human leukemias to bryostatin 1.

Kraft, A. S., William, F., Pettit, G. R., & Lilly, M. B. (1989) · PubMed · Cited by 71 · see citing works

Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non–Small-Cell Lung Cancer

Oh, Y. W., Herbst, R. S., Burris, H. A., Cleverly, A., Musib, L. C., Lahn, M., & Bepler, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3685 · Cited by 69 · see citing works

Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology

Keyes, K. A., Mann, L. L., Cox, K. L., Treadway, P., Iversen, P. W., Chen, Y.-F., & Teicher, B. A. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0572-5 · Cited by 63 · see citing works

Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells

Drexler, H. G., Gignac, S. M., Jones, R., Cs, S., Pettit, G., & Hoffbrand, A. V. (1989) · Blood · doi:10.1182/blood.v74.5.1747.bloodjournal7451747 · Cited by 63 · see citing works

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies

Podar, K., Raab, M. S., Chauhan, D., & Anderson, K. C. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.10.1693 · Cited by 56 · see citing works

Centrosomal PKCβII and Pericentrin Are Critical for Human Prostate Cancer Growth and Angiogenesis

Kim, J., Choi, Y., Vallentin, A., Hunrichs, B. S., Hellerstein, M. K., Peehl, D. M., & Mochly‐Rosen, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6195 · Cited by 54 · see citing works

Fine Tuning of Protein Kinase C (PKC) Isoforms in Cancer: Shortening the Distance from the Laboratory to the Bedside

Bosco, R., Melloni, E., Celeghini, C., Rimondi, E., Vaccarezza, M., & Zauli, G. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711795049899 · Cited by 53 · see citing works

A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas

Kreisl, T. N., Kim, L., Moore, K., Duic, P., Kotliarova, S. E., Walling, J., Musib, L. C., Thornton, D., Albert, P. S., & Fine, H. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3071 · Cited by 52 · see citing works

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

Rademaker-Lakhai, J. M., Beerepoot, L. V., Mehra, N., Radema, S. A., van Maanen, R. J., Vermaat, J. S. P., Witteveen, E. O., Visseren‐Grul, C., Musib, L. C., Enas, N. H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2912 · Cited by 52 · see citing works

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells

Tekle, C., Giovannetti, E., Sigmond, J., Graff, J. R., Smid, K., & Peters, G. J. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604566 · Cited by 45 · see citing works

Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β Inhibitor

Green, L. J., Marder, P., RAY, C. A., Cook, C. A., Jaken, S., Musib, L. C., Herbst, R. S., Carducci, M., Britten, C. D., Basche, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2231 · Cited by 45 · see citing works

A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas

Odia, Y., IWAMOTO, F. M., Moustakas, A., Fraum, T. J., Salgado, C. A., Li, A., Kreisl, T. N., Sul, J., Butman, J. A., & Fine, H. A. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2020-x · Cited by 44 · see citing works

STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1

Battle, T. E., & Frank, D. A. (2003) · Blood · doi:10.1182/blood-2002-09-2972 · Cited by 43 · see citing works

The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials

Zhang, L. L., Cao, F. F., Wang, Y., Meng, F. L., Zhang, Y., Zhong, D., & Zhou, Q. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1241-3 · Cited by 41 · see citing works

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study

Butowski, N. A., Chang, S. M., Lamborn, K. R., Polley, M. Y., Parvataneni, R., Hristova‐Kazmierski, M. K., Musib, L. C., Nicol, S. J., Thornton, D., & Prados, M. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop070 · Cited by 40 · see citing works

The oral protein-kinase Cβinhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines

Neri, A., Marmiroli, S., Tassone, P., Lombardi, L., Nobili, L., Verdelli, D., Civallero, M., Cosenza, M., Bertacchini, J., Federico, M., et al. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802078289 · Cited by 36 · see citing works

PHORBOL ESTER RECEPTORS AND THE IN VITRO EFFECTS OF TUMOR PROMOTERS

Blumberg, P. M., Delclos, K. B., Dunn, J. A., Jaken, S., Leach, K. L., & Yeh, E. (1983) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1983.tb47836.x · Cited by 36 · see citing works

Specific role for protein kinase C beta in cell differentiation.

Gamard, C. J., Blobe, G. C., Hannun, Y. A., & Obeid, L. M. (1994) · PubMed · Cited by 36 · see citing works

Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer

Socinski, M. A., Raju, R. N., Stinchcombe, T. E., Kocs, D. M., Couch, L. S., Barrera, D., Rousey, S. R., Choksi, J. K., Jotte, R. M., Patt, D. A., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fd42eb · Cited by 35 · see citing works

Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in vitro soft-agar cloning experiments

Hanauske, A.-R., Oberschmidt, O., Hanauske-Abel, H. M., Lahn, M. M. F., & Eismann, U. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9038-7 · Cited by 34 · see citing works

Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma

Querfeld, C., Kuzel, T. M., Kim, Y. H., Porcu, P., Duvic, M. A., Musiek, A. C. M., Rook, A. H., Mark, L. A., Pinter‐Brown, L. C., Hamid, O., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.572265 · Cited by 33 · see citing works

Differential effects of bryostatin 1 on human non-hodgkin's B-lymphoma cell lines

Mohammad, R. M., Al-Katib, A. M., Pettit, G. R., & Sensenbrenner, L. (1993) · Leukemia Research · doi:10.1016/0145-2126(93)90134-7 · Cited by 29 · see citing works

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

Camidge, D. R., Eckhardt, S. G., Gore, L., O’Bryant, C. L., Leong, S., Basche, M., Holden, S. N., Musib, L. C., Baldwin, J., Darstein, C., et al. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f077b3 · Cited by 27 · see citing works

Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116

Casey, E. M., Harb, W. A., Bradford, D. S., Bufill, J. A., Nattam, S. R., Patel, J., Fisher, W. B., Latz, J. E., Li, X., Wu, J., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ee820c · Cited by 25 · see citing works

A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer

Glimelius, B. L. G., Lahn, M. M. F., Gawande, S. R., Cleverly, A., Darstein, C., Musib, L. C., Liu, Y., Spindler, K.-L. G., Frödin, J., Berglund, Å., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp521 · Cited by 25 · see citing works

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer

Grønberg, B. H., Ciuleanu, T., Fløtten, Ø., Knuuttila, A., Abel, E., Langer, S. W., Krejcy, K., Liepa, A. M., Muñoz, M. D. M., Hahka‐Kemppinen, M., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.07.007 · Cited by 23 · see citing works

A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma

Jourdan, É., Leblond, V., Maisonneuve, H., Benhadji, K. A., Hossain, A. M., Nguyen, T. S., Wooldridge, J. E., & Moreau, P. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.861066 · Cited by 17 · see citing works

The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line

Hagiwara, K., Kunishima, S., Iida, H., Miyata, Y., Naoe, T., & Nagai, H. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1125-1 · Cited by 16 · see citing works

Open‐label, single‐arm, phase II study of enzastaurin in patients with follicular lymphoma

Schwartzberg, L. S., Hermann, R., Flinn, I. W., Flora, D. B., Hsi, E. D., Hamid, O., Shi, P., Lin, B. K., Myrand, S. P., Nguyen, T. S., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12853 · Cited by 15 · see citing works

A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study

Kilburn, L. B., Koçak, M., Decker, R., Wetmore, C., Chintagumpala, M., Su, J. M. F., Goldman, S., Banerjee, A., Gilbertson, R. J., Fouladi, M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou114 · Cited by 13 · see citing works

Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX), followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled phase II study

Wolfgang, W. W., Combs, S. E., Platten, M., Weller, M., Ohnmacht, U., Stoffregen, C., & Thornton, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e13038 · Cited by 10 · see citing works

Pharmacogenetic study in patients (pts) with metastatic breast (BC) and colorectal cancer (CRC) treated with Capecitabine (C)

Ribelles, N., Sánchez, A., Siles, J. L., González‐Flores, E., Sánchez, M. J., Carabantes, F., Sánchez‐Rovira, P., Márquez, A., Sevilla, I., & Alba, E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2005 · Cited by 10 · see citing works

Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study

Glimelius, B. L. G., Spindler, K.-L. G., Frödin, J., Berglund, Å., Byström, P., Qvortrup, C., Jakobsen, A. K. M., & Pfeiffer, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp526 · Cited by 6 · see citing works

Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development

Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9372182 · Cited by 608 · see citing works

Marine Natural Products: A Source of Novel Anticancer Drugs

Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555 · see citing works

Lithium and Therapeutic Targeting of GSK-3

Snitow, M. E., Bhansali, R. S., & Klein, P. S. (2021) · Cells · doi:10.3390/cells10020255 · Cited by 145 · see citing works

Recent advances in the pathogenesis of microvascular complications in diabetes

Park, S., Kang, H., Jeon, J., Kim, M., & Lee, I. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01130-3 · Cited by 69 · see citing works

Equivocal, explicit and emergent actions of PKC isoforms in cancer

Parker, P. J., Brown, S. J., Calleja, V., Chakravarty, P., Cobbaut, M., Linch, M., Marshall, J. J. T., Martini, S., McDonald, N. Q., Soliman, T., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00310-4 · Cited by 65 · see citing works

LncRNA VEAL2 regulates PRKCB2 to modulate endothelial permeability in diabetic retinopathy

Sehgal, P., Mathew, S., Sivadas, A., Ray, A., Tanwar, J., Vishwakarma, S., Ranjan, G., Vellarikkal, S. K., Bhoyar, R. C., Pateria, A., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020107134 · Cited by 58 · see citing works

Fixing the Unfixable: The Art of Optimizing Natural Products for Human Medicine

Yñigez‐Gutierrez, A. E., & Bachmann, B. O. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00246 · Cited by 48 · see citing works

A Systematic Review of Recently Reported Marine Derived Natural Product Kinase Inhibitors

Li, T., Wang, N., Zhang, T., Zhang, B., Sajeevan, T. P., Joseph, V., Armstrong, L., He, S., Yan, X., & Naman, C. B. (2019) · Marine Drugs · doi:10.3390/md17090493 · Cited by 47 · see citing works

An Update on Protein Kinases as Therapeutic Targets—Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases

Silnitsky, S., Rubin, S. J. S., Zerihun, M., & Qvit, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417600 · Cited by 42 · see citing works

Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational research

Khaldoyanidi, S. K., Hindoyan, A. A., Stein, A. S., & Subklewe, M. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103710 · Cited by 38 · see citing works

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma

He, Y., Li, J., Ding, N., Wang, X., Deng, L., Xie, Y., Ying, Z., Liu, W., Ping, L., Zhang, C., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1076-4 · Cited by 33 · see citing works

Drug repositioning in pulmonary arterial hypertension: challenges and opportunities

Grinnan, D., Trankle, C. R., Andruska, A., Bloom, B. E., & Spiekerkoetter, E. F. (2019) · Pulmonary Circulation · doi:10.1177/2045894019832226 · Cited by 29 · see citing works

Health position paper and redox perspectives – Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases

Cuadrado, A., Cazalla, E., Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, R., Grochot-Przeczek, A., Hayes, J. D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103569 · Cited by 28 · see citing works

Perspectives on the Clinical Development of NRF2-Targeting Drugs

Lastra, D., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_381 · Cited by 28 · see citing works

A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignancies

Liu, X., Devadiga, S. A., Stanley, R. F., Morrow, R. M., Janssen, K. A., Quesnel-Vallières, M., Pomp, O., Moverley, A. A., Li, C., Skuli, N., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175619 · Cited by 25 · see citing works

LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia

Ma, G., Gezer, D., Herrmann, O., Feldberg, K., Schemionek, M., Jawhar, M., Reiter, A., Brümmendorf, T. H., Koschmieder, S., & Chatain, N. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23131 · Cited by 24 · see citing works

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment

van Andel, L., Rosing, H., Schellens, J. H. M., & Beijnen, J. H. (2018) · Marine Drugs · doi:10.3390/md16070246 · Cited by 23 · see citing works

ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1

Nowakowski, G. S., Zhu, J., Zhang, Q., Brody, J., Sun, X., Maly, J. J., Song, Y., Rizvi, S., Song, Y., Lansigan, F., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0176 · Cited by 23 · see citing works

Marine-Derived Bisindoles for Potent Selective Cancer Drug Discovery and Development

Xu, M., Bai, Z., Xie, B., Peng, R., Du, Z., Liu, Y., Zhang, G., Yan, S., Xiao, X., & Qin, S. (2024) · Molecules · doi:10.3390/molecules29050933 · Cited by 21 · see citing works

Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review

Masnikosa, R., Cvetković, Z., & Pirić, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111384 · Cited by 21 · see citing works

Protein Kinase C Family: Structures, Biological Functions, Diseases, and Pharmaceutical Interventions

Li, Y., Jiang, Y.-H., Hu, Z.-X., Yang, S., Li, L., Xiong, C., Gao, Y., Sun, W.-G., & Zhang, Y.-H. (2025) · MedComm · doi:10.1002/mco2.70474 · Cited by 23 · see citing works

3,3’-Diindolylmethane and its derivatives: nature-inspired strategies tackling drug resistant tumors by regulation of signal transduction, transcription factors and microRNAs

Biersack, B. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.53 · Cited by 20 · see citing works

High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy

Cheng, C., Reis, S. A., Adams, E. T., Fass, D. M., Angus, S. P., Stuhlmiller, T. J., Richardson, J. I., Olafson, H. R., Wang, E. T., Patnaik, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-96227-5 · Cited by 20 · see citing works

A review on the relationship of mast cells and macrophages in breast cancer — Can herbs or natural products facilitate their anti-tumor effects?

Gou, L.-L., Yue, G. G., Puno, P. T., & Lau, C. B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105321 · Cited by 19 · see citing works

Emerging pharmaceutical therapies of Ascidian-derived natural products and derivatives

Cooreman, K., Spiegeleer, B. M. J. D., Poucke, C. V., Vanavermaete, D., Delbare, D., Wynendaele, E., & Witte, B. D. (2023) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2023.104254 · Cited by 16 · see citing works

The Protein Kinase Inhibitor Midostaurin Improves Functional Neurological Recovery and Attenuates Inflammatory Changes Following Traumatic Cervical Spinal Cord Injury

Zavvarian, M.-M., Hong, J., Khazaei, M., Chio, J. C. T., Wang, J., Badner, A., & Fehlings, M. G. (2021) · Biomolecules · doi:10.3390/biom11070972 · Cited by 13 · see citing works

Recent advances in PKC inhibitor development: Structural design strategies and therapeutic applications

Li, W., Zhu, K., Liu, Y., Liu, M., & Chen, Q. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117290 · Cited by 12 · see citing works

Drug Repurposing and Systems Biology approaches of Enzastaurin can target potential biomarkers and critical pathways in Colorectal Cancer

Somadder, P. D., Hossain, M. A., Ahsan, A., Sultana, T., Soikot, S. H., Rahman, M. M., Ibrahim, S. M., Ahmed, K., & Bui, F. M. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106630 · Cited by 11 · see citing works

Combination of enzastaurin and ATRA exerts dose-dependent dual effects on ATRA-resistant acute promyelocytic leukemia cells.

Cui, L., Ding, M., Weng, X., Sheng, Y., Wu, J., Li, Z.-Y., & Cai, X. (2019) · PubMed Central · Cited by 10 · see citing works

Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection

Hedrich, W. D., & Wang, H. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-02997-y · Cited by 9 · see citing works

Analyzing the ER stress response in ALS patient derived motor neurons identifies druggable neuroprotective targets

Watts, M. E., Giadone, R. M., Ordureau, A., Holton, K. M., Harper, J. W., & Rubin, L. L. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1327361 · Cited by 7 · see citing works

Critical role of caveolin-1 in intestinal ischemia reperfusion by inhibiting protein kinase C βII

Chen, Z., Wang, Z., Liu, D., Zhao, X., Ning, S., Liu, X., Wang, G., Zhang, F., Luo, F., Yao, J., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.11.030 · Cited by 7 · see citing works

Colistin enhances caspofungin antifungal efficacy against Aspergillus fumigatus by modulating calcium homeostasis and stress responses

García-Carnero, L. C., Li, X., de Castro, P. A., Pinzan, C. F., Campanella, J. E. M., Malavazi, I., Yoshimura, M., Isuhuaylas, L. A. V., Yashiroda, Y., Boone, C. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60991-z · Cited by 6 · see citing works

BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia

Chohan, K. L., & Kapoor, P. (2023) · Hemato · doi:10.3390/hemato4020012 · Cited by 6 · see citing works

The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats

Willeman, M. N., Mennenga, S. E., Siniard, A. L., Corneveaux, J. J., Both, M. D. D., Hewitt, L. T., Tsang, C. W. S., Caselli, J., Braden, B. B., Bimonte‐Nelson, H. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198256 · Cited by 6 · see citing works

Evaluation of current mouse in vivo models and advanced in vitro models for leukaemia research

Bubnova, X., Hope, L., & Wheadon, H. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101318 · Cited by 5 · see citing works

Integrated Machine Learning and Structure-Based Virtual Screening Identify Osimertinib as a TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Zhao, L., Liu, H., Yao, X., Ma, X., Liu, B., Li, B., Tong, H. H. Y., & Zhang, Q. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01521 · Cited by 4 · see citing works

Enzastaurin enhances ATRA-induced differentiation of acute myeloid leukemia cells.

Li, Z.-Y., Cui, L., Ding, M., Weng, X., Sheng, Y., Wu, J., Lü, H., & Cai, X. (2020) · Europe PMC (PubMed Central) · Cited by 4 · see citing works

Reawakening Differentiation Therapy in Acute Myeloid Leukemia: A Comprehensive Review of ATRA-Based Combination Strategies

Takahashi, S. (2026) · Current Oncology · doi:10.3390/curroncol33010025 · Cited by 3 · see citing works

Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials

Liu, X., Chen, Z., Wang, X., Yan, P., Zong, D., Guo, W., & He, X. (2025) · iScience · doi:10.1016/j.isci.2025.113521 · Cited by 2 · see citing works

Non-Pharmaceutical Interventions in Cancer Therapy

Tyagi, V., Tanwar, N., Kumar, N., Phogat, N., Kumar, P., & Kumar, V. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947268161240404084729 · Cited by 2 · see citing works

Tigilanol Tiglate-Induced Changes in Secretome Profiles Alter C-Met Phosphorylation and Cell Surface Protein Expression in H357 Head and Neck Cancer Cells

Antwi, F. D., Awad, T., Larin, M., Heesom, K. J., Lewis, P. A., Reddell, P. W., Poghosyan, Z. P., Dewitt, S., Moseley, R., & Knäuper, V. (2024) · Cells · doi:10.3390/cells13110982 · Cited by 2 · see citing works

The Sources, Structures and Cytotoxicity of Animal‐Derived Bisindole Compounds

Zhang, Z., Xu, H., Gong, C., Li, Y., Li, Y., Song, X., Wang, R., & Zhang, D. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401165 · Cited by 2 · see citing works

Indole-3-carbinol prevented tumor progression and potentiated PD1ab therapy by upregulating PTEN in colorectal cancer

Chen, H., Gao, B., Li, J., Liu, L., Zhang, Y., Shuai, M., & Ji, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-01887-8 · Cited by 2 · see citing works

Modular Maleimide Synthesis from Ynamides

Heymans, T., Durand-Baudet, L., Landrain, Y., & Evano, G. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c02117 · Cited by 1 · see citing works

Anticancer drugs acting on signaling pathways, part 2: Inhibitors of serine-threonine kinases and miscellaneous signaling pathways

Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00011-x · Cited by 1 · see citing works

Targeting PKC as a Therapeutic Strategy to Overcome Chemoresistance in TNBC by Restoring Aurora Kinase B Expression

Cheng, B., Chen, J., Katalina, V., Long, G., Wei, C., Niu, Z., Chen, C., Wang, P., Yu, Q., & Wang, W. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70464 · Cited by 1 · see citing works

Growth Factor Signaling Pathways and Targeted Therapy

Swanson, K. D., Charest, A., Pollack, I. F., & Wong, E. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00021-8 · Cited by 1 · see citing works

Enzasataurin Enhances ATRA-induced Differentiation of Acute Myeloid Leukemia CellsPreprint

Li, Z.-Y., Cui, L., Ding, M., Weng, X., Sheng, Y., Wu, J., Lu, H., & Cai, X. (2020) · doi:10.21203/rs.3.rs-38343/v1 · Cited by 1 · see citing works

Integrative analysis of immune infiltration and microenvironment characteristics in renal clear cell carcinoma induced by cell senescencePreprint

Zhang, X., Wang, X., Li, H., Wang, X., Zhang, M., Liu, Y., & Li, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2492545/v1

Growth factor signaling pathways and targeted therapy

Aulakh, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00061-9

Protein kinase C in neurodegenerative disorders

Hekmat, A., & Saboury, A. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44173-8.00013-9

Synthesis of ACT-007 and Its Analogues with Antiproliferative Activity

Wang, Y., Chen, L., Wen, Q., Liu, Y., Gao, Y., Wang, L., & Zhu, W. (2026) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6c00922

Lipid regulation of mitochondrial function in metabolic Diseases: Lipotoxic mediators and therapeutic targeting

Cui, H., Li, H., Wang, W., Li, J., Cai, M., Wang, Y., Zhang, Y., & Li, S. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118475

Antitumor bisindole alkaloids

Qin, S., & 肖小河 (2026) · Studies in natural products chemistry · doi:10.1016/b978-0-443-51068-7.00009-x

Enzastaurin

Chen, Y., & LaCasce, A. S. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.939 · Cited by 46 · see citing works

Enzastaurin, a Protein Kinase Cβ–Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer

Herbst, R. S., Oh, Y. W., Wagle, A., & Lahn, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0538 · Cited by 37 · see citing works

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

Camidge, D. R., Eckhardt, S. G., Gore, L., O’Bryant, C. L., Leong, S., Basche, M., Holden, S. N., Musib, L. C., Baldwin, J., Darstein, C., et al. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f077b3 · Cited by 27 · see citing works

Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer

Carducci, M. A., Musib, L. C., Kies, M. S., Пили, Р., Truong, M. T., Brahmer, J. R., Cole, P., Sullivan, R., Riddle, J. R., Schmidt, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3447 · Cited by 176 · see citing works

A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer

Leong, S., Camidge, D. R., Eckhardt, G., Basche, M., Musib, L. C., Darstein, C., Thornton, D., & Britten, C. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.2048 · Cited by 9 · see citing works